Blue Sail Medical Reports H1 2025 Net Loss Exceeding RMB 100 Million Amid Strategic Investments and Business Restructuring

Jul 15, 2025 17:27 CST Updated 17:27

Bluesail Medical

Producers of Medium-Low Value Consumables and High-Value Medical Devices

BrioHealth Solutions

Ventricular Assist Device Developer and Manufacturer

July 14, 2025Bluesail Medical Co., Ltd.(Stock Code: 002382) Released the 2025 Semi-Annual Earnings Forecast.

According to the announcement, the company expects to achieve a net profit attributable to shareholders of the listed company in the first half of 2025.Loss of 100 million to 150 million yuan, narrowed compared to a loss of 160 million yuan in the same period last year, year-on-yearIncreased by 6.38% to 37.58%Net profit after deducting non-recurring gains and lossesLoss of 170 million to 230 million yuan, with a year-on-year change ranging from -17.11% to 13.44%.

Reasons for Performance Change

Investment Loss: BrioHealth Solutions, in which Bluesail Medical Co., Ltd. holds a stake, completed its pre-IPO financing at the end of June 2025. The change in its valuation led to a fair value loss of approximately 120 million yuan (non-cash outflow) for Bluesail Medical, impacting the performance of the company's cardiovascular division.
Improvement in Cardiovascular and Cerebrovascular Business: Excluding the Suzhou BrioHealth Solutions matter, the cardiovascular and cerebrovascular business division's operating performance continues to improve. In the first half of 2025, sales revenue exceeded 690 million yuan, with a year-on-year increase of over 20%. The sales expense ratio and management expense ratio further decreased, achieving a turnaround from losses and contributing significant profits.
Financial Cost Pressure: Due to the financial liabilities formed by the introduction of strategic investment in subsidiaries in 2024, financial expenses of 25 million yuan (non-cash outflow) were accrued in the second quarter of 2025. Together with headquarters management fees, etc., this further impacted profits.
Protection Business Under Pressure: The Health Protection Division incurred losses due to fluctuations in overseas orders and a decline in sales prices.

# About Bluesail Medical

Bluesail Medical Co., Ltd.(abbreviated as "Bluesail Medical", stock code: 002382) was established in 2002. It is a leading medical device company with a complete layout covering both low-to-mid value and high-value consumables, and it was successfully listed on the Shenzhen Stock Exchange on April 2, 2010.

Bluesail Medical's business layout covers four major segments:

Cardio-Cerebrovascular Business Unit: InCardiac StentAt the core, a comprehensive layout of interventional devices.
Health Protection Division: InMedical GlovesAt the core, comprehensively layout medical protection and epidemic prevention products.
Surgical Division: InStapler and Ultrasonic ScalpelAt the core, a comprehensive layout of minimally invasive surgical instruments.
Nursing Division:First Aid KitAt the core, comprehensively layout emergency care products.

Bluesail Medical is in a leading position in the medical device industry. It has a rich product line.Covering coronary, structural heart disease, peripheral and neuro-intervention, etc.In multiple fields. The company has further consolidated its competitiveness in the cardiovascular and cerebrovascular field through mergers, acquisitions, and investments.

For example, Bluesail Medical in 2018Acquired Biosensors International, a Singapore-based multinational device company, for 5.9 billion yuan, and has gained a globally leading platform for high-value cardiovascular consumables.

Representative Products

BioFreedom^®Drug-Coated Coronary Stent System

Biosensors International's flagship product, using SMS technology to carry the exclusive patented BA9 anti-proliferative drug. Due to the drug's high lipophilicity, it enables single-sided drug loading on the stent surface and targeted drug release without the need for polymers.

Large-scale clinical study LEADERS FREE has confirmed thatSafety and Efficacy of BioFreedom in High Bleeding Risk (HBR) Populations, which can significantly shorten the postoperative dual antiplatelet therapy course to just one month, bringing obvious benefits to HBR patients;

Currently, it has obtained certifications from four major institutions: CE, Japan PMDA, China NMPA, and the U.S. FDA., and obtain the HBR indication in four major markets.

Biotron^®Umibomus Coated Coronary Balloon Dilation Catheter

The First Morus Drug Balloon in China, equipped with the latest generation of rapamycin derivative——BA9, which is characterized by high lipophilicity and long-lasting efficacy, addressing the issues of slow tissue absorption and short retention time in tissues commonly associated with traditional mTOR inhibitor drugs;

Unique crystallization process combined with PEO hydrophilic coating,Significantly improve the stability and integrity of the drug coating, overcoming the barrier of applying rapamycin-based drugs to drug-coated balloons.。

HeartLeap^®Drug-Coated Stent System (Rapamycin)

Upgrade Platform Based on the Advanced Design Concept of the First-Generation Stent Product AccellAdopting the brand-new generation of cobalt-chromium alloy stent platform CHROMA；

The dose of rapamycin was reduced by two-thirds, accelerating the endothelialization process while maintaining effective anti-proliferative effects, further improving patient prognosis.

In the 2020 China coronary artery stent procurement, BrioHealth Solutions ranked first and was awarded the bid. It provided more medical institutions and patients with the latest generation of drug-eluting stents featuring excellent operational performance at a more reasonable price.

SiYu Annual Activity Review:The First Global Ophthalmology Conference | The First Global Orthopedics Conference | The First Global Cardiovascular Conference| The First Global Medical Aesthetics Technology Conference

Coming Soon:

July 17, 2025, The Second Global Medical Technology Conference

September 3-5, 2025, The 3rd Global Surgical Robotics Conference